All treatments
Treatment
BIMERVAX emulsion for injection COVID-19 Vaccine (recombinant clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coronavirus disease 2019 (COVID-19) in adolescents from 12 years to less than 18 years of age.
This study is looking at a new COVID-19 booster vaccine called BIMERVAX for teenagers aged 12 to 17. It aims to see if BIMERVAX is as safe and effective as another vaccine, HIPRA-HH-2, in boosting protection against the Omicron variant of COVID-19.
For: SARS-CoV-2 infectionSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
This study is testing a new COVID-19 vaccine, BIMERVAX®, when given at the same time as a regular flu jab. We want to see if it's safe and how well it helps your body fight off viruses in people over 65.
For: SARS-CoV-2 and InfluenzaSpain